Role of Angiotensin II in Insulin-induced Microvascular Activity
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Maastricht, P.o. Box 5800, Netherlands, Netherlands, 6202 AZ
- Maastricht University Medical Centre
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
1.18-60 years 2.Caucasian 3.Blood pressure <140/90 mmHg.
Exclusion Criteria:
- Obesity (BMI>27kg/m2)
- Cardiovascular disease (stroke, coronary artery disease, peripheral vascular disease, heart failure)
- Impaired glucose tolerance or diabetes mellitus according to the criteria of the ADA
- Smoking
- Alcohol use >4U/day
- Use of medication (antihypertensive drugs, lipid lowering drugs, corticosteroids, NNSAIDs)
- Pregnancy
- Wearing contact lenses
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Sham Comparator: Placebo
|
|
|
Experimental: Angiotensin II
|
Angiotensin II
|
|
Active Comparator: Phenylephrine
|
Phenylephrine
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
functional recruitment of capillaries in the skin
Time Frame: January 2009
|
January 2009
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
perfused capillary density in the nailfold
Time Frame: January 2009
|
January 2009
|
|
Endothelium- (in)dependent vasodilatation of finger skin microcirculation
Time Frame: January 2006
|
January 2006
|
|
Insulin sensitivity
Time Frame: January 2009
|
January 2009
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: CDA Stehouwer, Prof, Maastricht University Medical Centre
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Hyperinsulinism
- Insulin Resistance
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Protease Inhibitors
- Protective Agents
- Adrenergic alpha-Agonists
- Adrenergic Agonists
- Cardiotonic Agents
- Respiratory System Agents
- Serine Proteinase Inhibitors
- Sympathomimetics
- Vasoconstrictor Agents
- Mydriatics
- Nasal Decongestants
- Adrenergic alpha-1 Receptor Agonists
- Phenylephrine
- Oxymetazoline
- Angiotensin II
- Giapreza
- Angiotensinogen
Other Study ID Numbers
Other Study ID Numbers
- MEC 06-2-074
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.